Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions
Cataract
Interventions
DRUG

Clobetasol propionate

Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)

DRUG

Vehicle

Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance

Trial Locations (22)

10028

Fifth Avenue Eye Associates, New York

30076

Coastal Research Associates, Roswell

30260

Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow

31701

Dixon Eye Care, Albany

33904

Arus Research at Cape Coral Eye Center, Cape Coral

45014

Apex Eye, Mason

57701

Black Hills Regional Eye Institute, Rapid City

60169

Chicago Cornea Consultants Ltd, Hoffman Estates

60619

Chicago Eye Specialists, Chicago

64133

Silverstein Eye Centers, Kansas City

77025

Houston Eye Associates, Houston

78240

Medical Center Ophthalmology Associates, San Antonio

78731

Texan Eye, PA / Keystone Research Ltd., Austin

85224

Arizona Eye Center, Chandler

89119

Wellish Vision Institute, Las Vegas

90210

Beverly Hills Institute of Ophthalmology, Beverly Hills

90505

Wolston & Goldberg Eye Associates, Torrance

91105

Pasedena Eye Medical Group, Pasadena

92562

LoBue Laseer & Eye Medical Center, Murrieta

93105

Santa Barbara Eyecare, Santa Barbara

95670

Mark B. Kislinger, MD, Inc., Glendora

Martel Medical Eye Group, Rancho Cordova

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Salvat

INDUSTRY